drugset / Trial / NCT02700919

Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease

NCT02700919

Phase 2 Completed 282 enrolled Mereo BioPharma
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to compare the efficacy and safety of BCT197 when added on to standard of care in adult subjects with acute respiratory exacerbations of chronic obstructive pulmonary disease requiring hospitalization. Additionally, the study will characterize the pharmacokinetics of BCT197 in adults with COPD. The total duration of the study will be 26 weeks. Subjects will receive study treatment administration over a period of 5 days after randomization. It is expected that approximately 255 subjects will complete the study and follow-up.

Timeline

Start
2016-08-01
Primary completion
2017-11-08
Completion
2017-11-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Acumapimod Small molecule Oral